{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T18:41:43Z","timestamp":1774204903055,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2009,10,8]],"date-time":"2009-10-08T00:00:00Z","timestamp":1254960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Economics"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Real options analysis is a promising approach to model investment under uncertainty. We employ this approach to value stockpiling of antiviral drugs as a precautionary measure against a possible influenza pandemic. Modifications of the real options approach to include risk attitude and deviations from expected utility are presented. We show that risk aversion counteracts the tendency to delay investment for this case of precautionary investment, which is in contrast to earlier applications of risk aversion to real options analysis. Moreover, we provide a numerical example using real world data and discuss the implications of real options analysis for health policy. Suggestions for further extensions of the model and a comparison with the expected value of information analysis are put forward. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hec.1549","type":"journal-article","created":{"date-parts":[[2009,10,8]],"date-time":"2009-10-08T16:09:14Z","timestamp":1255018154000},"page":"1240-1254","source":"Crossref","is-referenced-by-count":19,"title":["Investment in antiviral drugs: a real options approach"],"prefix":"10.1002","volume":"19","author":[{"given":"Arthur E.","family":"Attema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.","family":"Lugn\u00e9r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talitha L.","family":"Feenstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,10,8]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.46.11.1497.12080"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1108.041156"},{"key":"e_1_2_11_4_1","volume-title":"Dynamic Programming and Stochastic Control","author":"Bertsekas DP","year":"1976"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1339"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.47.11.1498.10248"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.45.5.670"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta3020"},{"key":"e_1_2_11_9_1","first-page":"2075","article-title":"Richtlijnen en kosten","volume":"142","author":"Casparie AF","year":"1998","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"key":"e_1_2_11_10_1","unstructured":"CBS. Harmonized Consumer Price Index. Available at:http:\/\/statline.cbs.nl\/statweb\/[15 September2008]."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(98)00039-3"},{"key":"e_1_2_11_12_1","volume-title":"Guidelines for Pharmacoeconomic Research","author":"CvZ","year":"2006"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1515\/9781400830176"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06297390"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1958.02990100028006"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X07312477"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-9883(88)90023-0"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2979.2007.00270.x"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06290493"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025576823096"},{"key":"e_1_2_11_21_1","unstructured":"Health Council of the Netherlands.2005.Use of Antiviral Agents and Other Measures in an Influenza Pandemic. Health Council of the Netherlands publication no. 2005\/05: The Hague (in Dutch)."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1257\/000282802762024700"},{"key":"e_1_2_11_23_1","doi-asserted-by":"crossref","unstructured":"HugonnierJ MorellecE.2007. Real options and risk aversion. Swiss Finance Institute Research Paper. Available at:http:\/\/ssrn.com\/abstract=422600 DOI:10.2139\/ssrn.422600.","DOI":"10.2139\/ssrn.422600"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1353\/bhm.2002.0022"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2307\/1914185"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1062-9769(99)80097-0"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-6296(94)00044-5"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1201.050556"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckp119"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1485"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.043"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00069-0"},{"key":"e_1_2_11_33_1","volume-title":"Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg","author":"Oostenbrink J","year":"2004"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(00)00048-5"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0377-2217(96)00283-4"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.06.007"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1402.070478"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1257\/jel.38.2.332"},{"key":"e_1_2_11_39_1","volume-title":"Real Options: Managerial Flexibility and Strategy in Resource Allocation","author":"Trigeorgis L","year":"1996"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00122574"},{"key":"e_1_2_11_41_1","doi-asserted-by":"crossref","unstructured":"van den GoorberghRWJ HuismanKJM KortPM.2003.Risk aversion price uncertainty and irreversible investments. University of Tilburg Discussion paper 2003\u2010119.","DOI":"10.2139\/ssrn.556955"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1331"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1090350"},{"key":"e_1_2_11_44_1","volume-title":"Report WHO\/CDS\/CSR\/GIP\/2005.5","author":"WHO","year":"2005"}],"container-title":["Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhec.1549","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hec.1549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T03:23:16Z","timestamp":1698636196000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hec.1549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,8]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1002\/hec.1549"],"URL":"https:\/\/doi.org\/10.1002\/hec.1549","archive":["Portico"],"relation":{},"ISSN":["1057-9230","1099-1050"],"issn-type":[{"value":"1057-9230","type":"print"},{"value":"1099-1050","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,8]]}}}